10 most popular complementary medicines may interact with cancer therapy
the ONA take:
According to new research presented at the Clinical Oncology Society of Australia's (COSA's) Annual Scientific Meeting in Melbourne, Australia, researchers at Peter MacCallum Cancer Centre in Melbourne have found that the 10 most asked about complementary medicines all may result in drug interactions with administered with chemotherapy, radiation, or prior to surgery.
For the study, researchers identified the 10 most commonly inquired about complementary medicines by providers and patients to the hospital's Medicines Information Centre. Excluding vitamins and minerals, the 10 most commonly asked about complementary medicines were: astragalus, coenzyme Q10, fish oil, ginger, green tea, lactobacillus, licorice, milk thistle, and reishi mushroom.
The researchers note that any of those found in a normal healthy diet would not likely cause adverse effects, but higher quantities consumed in complementary medicines could. These supplemental medicines have the potential to alter the effects of chemotherapy, thereby increasing the patient's risk of toxicity or decreasing the effectiveness of the chemotherapy.
Products that contain high levels of antioxidants can potentially interact with chemotherapy and radiotherapy. Patients should be aware that a natural product may not be safe and a complementary product does not necessarily complement standard cancer therapies.
10 most asked about complementary medicines all may result in drug interactions.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|